Gene · 8505
Papers1,648
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,648
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Drugging the DNA damage response in the clinic: going beyond PARP. | Expert Rev Anticancer Ther | 2026 | 41086259 | PubTator, text mining | PubMed |
| PARG inhibition halts cholangiocarcinoma progression via the Hippo pathway and enhances response to chemotherapy and immunotherapy. | J Hepatol | 2026 | 41016443 | PubTator, text mining | PubMed |
| Replication-associated base excision repair/single-strand break repair regulates PARG inhibitor response via the PRMT1/PRMT5/ATR axis. | NAR Cancer | 2025 | 41480640 | PubTator, text mining | PubMed |
| Loss-of-function genetic screen unveils synergistic efficacy of PARG inhibition with combined 5-fluorouracil and irinotecan treatment in colorectal cancer. | Clin Transl Med | 2025 | 41451844 | PubTator, text mining | PubMed |
| Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy. | Nucleic Acids Res | 2025 | 41359388 | PubTator, text mining | PubMed |
| Targeting DNA Damage Repair Pathways Beyond PARP Inhibition. | Target Oncol | 2025 | 41240294 | PubTator, text mining | PubMed |
| Chromatin relaxation dynamics and histone PTMs in the early DNA damage response. | Cancer Biol Med | 2025 | 41078005 | PubTator, text mining | PubMed |
| Multi-omics analysis of parthanatos related molecular subgroup and prognostic model development in stomach adenocarcinoma. | PLoS One | 2025 | 41004487 | PubTator, text mining | PubMed |
| Discovery and Structural Optimization of 2-Hydrazinopyrimidin-4-one Analogs Inhibiting Human ADP-Ribosylhydrolase ARH3. | ACS Chem Biol | 2025 | 40952342 | PubTator, text mining | PubMed |
| Disordered Protein Tail Is Wagging Poly(ADP-ribosyl)ation. | Int J Mol Sci | 2025 | 40943096 | PubTator, text mining | PubMed |
| Deltex and RING-UIM E3 ligases cooperate to create a ubiquitin-ADP-ribose hybrid mark on tankyrase, promoting its stabilization. | Sci Adv | 2025 | 40901936 | PubTator, text mining | PubMed |
| Biomolecular phase separation in tumorigenesis: from aberrant condensates to therapeutic vulnerabilities. | Mol Cancer | 2025 | 40849651 | PubTator, text mining | PubMed |
| Poly (ADP-Ribose) Glycohydrolase-Dependent dePARylation of PCNA Is Essential for DNA Replication. | FASEB J | 2025 | 40827866 | PubTator, text mining | PubMed |
| Comprehensive landscape of cell death mechanisms: from molecular cross-talk to therapeutic innovation in oncology. | Front Cell Dev Biol | 2025 | 40741332 | PubTator, text mining | PubMed |
| Single nucleosome imaging reveals principles of transient multiscale chromatin reorganization triggered by histone ADP-ribosylation at DNA lesions. | Nat Commun | 2025 | 40683884 | PubTator, text mining | PubMed |
| PARPs and ADP-ribosyl hydrolases in cancer therapy: From drug targets to biomarkers. | DNA Repair (Amst) | 2025 | 40580812 | PubTator, text mining | PubMed |
| Occurrence and Drivers of Antibiotic Resistance Genes Carried by Bacteriophages in Soils Following Different Fertilization Treatments. | Toxics | 2025 | 40559968 | PubTator, text mining | PubMed |
| DNA polymerase beta expression in head & neck cancer modulates the poly(ADP-ribose)-mediated replication checkpoint. | DNA Repair (Amst) | 2025 | 40472742 | PubTator, text mining | PubMed |
| Liquid‒liquid phase separation and poly(ADP‒ribosyl)ation in the context of ultraviolet radiation-induced stress in mammalian cells. | Biophys Rev | 2025 | 40376396 | PubTator, text mining | PubMed |
| Adenosine diphosphate-ribosylation greatly affects proteins function: a focus on neurodegenerative diseases. | Front Aging Neurosci | 2025 | 40370754 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8505/papers?page=3